Swedbank AB Trims Holdings in United Therapeutics Corporation $UTHR

Swedbank AB lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.5% during the first quarter, Holdings Channel reports. The firm owned 330,513 shares of the biotechnology company’s stock after selling 4,992 shares during the quarter. Swedbank AB’s holdings in United Therapeutics were worth $101,887,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of UTHR. SVB Wealth LLC purchased a new position in shares of United Therapeutics during the 1st quarter worth approximately $32,000. Geneos Wealth Management Inc. grew its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the period. Sound Income Strategies LLC purchased a new position in shares of United Therapeutics during the 1st quarter worth approximately $49,000. Brooklyn Investment Group grew its holdings in shares of United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 98 shares during the period. Finally, WPG Advisers LLC purchased a new position in shares of United Therapeutics during the 1st quarter worth approximately $60,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $405.02 on Friday. The stock has a market capitalization of $18.27 billion, a price-to-earnings ratio of 15.81, a PEG ratio of 6.17 and a beta of 0.62. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $436.95. The business’s fifty day moving average price is $318.53 and its 200-day moving average price is $307.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter last year, the company earned $5.85 earnings per share. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 8,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total transaction of $3,188,400.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at $51,811.50. This represents a 98.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Insiders sold 128,816 shares of company stock valued at $45,836,113 in the last 90 days. Insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on UTHR shares. Jefferies Financial Group upped their target price on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Wells Fargo & Company upped their target price on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 3rd. HC Wainwright upped their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Friday, September 5th. Morgan Stanley cut their price target on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, JPMorgan Chase & Co. cut their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Nine equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $438.85.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.